Sorafenib in Treating Patients With Advanced Solid Tumors

Summary

This randomized phase I trial is studying the side effects, such as high blood pressure, and best dose of sorafenib in treating patients with advanced solid tumors. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Timeline

Start

2007-01

Primary completion

2011-09

Completion

—

Drugs

Indications